Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Biomarker and diagnostic research for idiopathic multicentric Castleman disease has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered. Interventions under study include drug therapy. Pipeline includes 1 PHASE2. Research is primarily sponsored by academic and government institutions.
129 publications have been identified in PubMed for idiopathic multicentric Castleman disease. Research spans Case Report / Case Series (43%), Review / Meta-Analysis (18%), and Other (9%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 55 | 43% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 6:56 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Research summaries |
23 |
18% |
Other research | 12 | 9% |
Laboratory research | 11 | 9% |
Disease patterns and progression | 11 | 9% |
Testing and diagnosis research | 8 | 6% |
Clinical study results | 8 | 6% |
New treatment approaches | 1 | 1% |
Fukui S (2026). [PMID: 41711072](https://pubmed.ncbi.nlm.nih.gov/41711072/). *Mod Rheumatol*. [Clinical Trial Publication]
Quon S (2026). [PMID: 41840344](https://pubmed.ncbi.nlm.nih.gov/41840344/). *Am J Hematol*. [Case Report / Case Series]
Pelliccia S (2026). [PMID: 41889412](https://pubmed.ncbi.nlm.nih.gov/41889412/). *Front Oncol*. [Other]
Umeda M (2026). [PMID: 41365367](https://pubmed.ncbi.nlm.nih.gov/41365367/). *Immunol Lett*. [Epidemiology / Natural History]
Ke H (2026). [PMID: 41693259](https://pubmed.ncbi.nlm.nih.gov/41693259/). *Br J Haematol*. [Case Report / Case Series]
Sastre Ortega J (2026). [PMID: 42014163](https://pubmed.ncbi.nlm.nih.gov/42014163/). *BMJ Case Rep*. [Case Report / Case Series]
Kamarádová K (2026). [PMID: 41996258](https://pubmed.ncbi.nlm.nih.gov/41996258/). *Cesk Patol*. [Review / Meta-Analysis]
Li S (2026). [PMID: 41726392](https://pubmed.ncbi.nlm.nih.gov/41726392/). *Hemasphere*. [Other]
Masuzawa N (2026). [PMID: 41975025](https://pubmed.ncbi.nlm.nih.gov/41975025/). *Clin Exp Nephrol*. [Epidemiology / Natural History]
Ueda Y (2026). [PMID: 41100060](https://pubmed.ncbi.nlm.nih.gov/41100060/). *Rheumatology (Oxford)*. [Epidemiology / Natural History]
AI-curated news mentioning idiopathic multicentric Castleman disease
Updated Aug 11, 2026
A new study outlines the development and validation of the Idiopathic Multicentric Castleman Disease Symptom Burden Scale (ISBUS). This international mixed methods study aims to enhance understanding of symptom burden in patients with idiopathic multicentric Castleman disease.
A recent study explores HIV-negative KSHV/HHV8-associated multicentric Castleman disease, highlighting its concurrent occurrence with Kaposi sarcoma and POEMS-like manifestations. This research adds to the understanding of complex interactions in rare diseases.
A study highlights the significance of serum interleukin-6 (IL-6) monitoring in patients with idiopathic multicentric Castleman disease undergoing non-anti-IL-6 therapy. This research underscores the potential for IL-6 levels to inform treatment decisions and patient management.